Correlation between gut microbiota and the development of Graves' disease: A prospective study/Experiment 5

From BugSigDB


Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Subjects

Location of subjects
China
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Graves disease Basedow disease,Basedow's disease,exophthalmic goiter,Flajani-Basedow-Graves disease,grave's disease,Graves disease,Graves' disease,Graves' hyperthyroidism,parry disease,toxic diffuse goiter,graves disease
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Graves’ disease without hepatic impairment (GDN)
Group 1 name Corresponds to the case (exposed) group for case-control studies
Graves’ disease with impaired liver function before treatment (GDH)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients with confirmed Graves’ disease (GD) and impaired liver function before treatment (GDH)
Group 0 sample size Number of subjects in the control (unexposed) group
47
Group 1 sample size Number of subjects in the case (exposed) group
18
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
Three months

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
Welch's T-Test
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
Yes


Signature 1

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 4A

Description: Differentially abundant taxa from the phylum to genus level were further analyzed between GDH and GDN subgroups by STAMP analysis using Welch’s ttest (p < 0.05, q < 0.05).

Abundance in Group 1: increased abundance in Graves’ disease with impaired liver function before treatment (GDH)

NCBI Quality ControlLinks
Coprococcus

Revision editor(s): Aleru Divine

Signature 2

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 4A

Description: Differentially abundant taxa from the phylum to genus level were further analyzed between GDH and GDN subgroups by STAMP analysis using Welch’s ttest (p < 0.05, q < 0.05).

Abundance in Group 1: decreased abundance in Graves’ disease with impaired liver function before treatment (GDH)

NCBI Quality ControlLinks
Pseudomonadota
Gammaproteobacteria
Enterobacterales
Enterobacteriaceae
Lactobacillaceae
Weissella

Revision editor(s): Aleru Divine